In response to the challenge that Medisafe users are more inclined to be

adherent with medication management, Medisafe created a study with IQVIA

to measure the impact that digital companions can have on a chronically

non-adherent patient population.

Medisafe’s study measured the impact of digital companions across three

therapeutic areas: hypertension, major depressive disorder, and diabetes on

over 4,000 patients.

Adherence was measured using the Medication Possession Ration (MPR)

identifying patients for this study with a MPR of <0.8 (pre-index before using

Medisafe). The study compared Medisafe users to a control group of non-

Medisafe users who had been prescribed their specific medication for use

between 2014 and 2017 to measure persistence.

Key Findings:

• More than 70% of patients became adherent
• Hypertension, diabetes and depression patients increased their median MPR to above 0.9 (out of a possible 1.0) after using Medisafe
• By month 12, hypertension and depression patients were 2-3x more likely to remain on therapy than the controls.
• By month 24, hypertension and depression patients were 6x more likely to remain on therapy than the controls.See all the results: Download the results:

See all the results (free, no registration required):

• Click here for IQVIA study on Adherence

• Click here for IQVIA study on Persistence